Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China

Trial Profile

Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 30 Jun 2017 Planned number of patients changed from 60 to 61.
    • 12 May 2017 Planned number of patients changed from 30 to 60.
    • 12 May 2017 Planned End Date changed from 21 Mar 2020 to 4 Sep 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top